Premium
[P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES
Author(s) -
Mueller Andre,
Kroth Heiko,
Schieferstein Hanno,
Berndt Mathias,
Oden Felix,
Capotosti Francesca,
Molette Jerome,
Juergens Tanja,
Darmency Vincent,
SchmittWillich Heribert,
Hickman David,
Tamagnan Gilles,
Pfeifer Andrea,
Dinkelborg Ludger,
Muhs Andreas,
Stephens Andrew
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1036
Subject(s) - human brain , chemistry , pittsburgh compound b , tauopathy , amyloid (mycology) , tau protein , dementia , tau pathology , binding selectivity , neuroscience , biochemistry , alzheimer's disease , biology , medicine , disease , neurodegeneration , inorganic chemistry
from 65 to 85% (FTD vs EAOD: 82%, EOAD vs Depression: 83%, FTD vs Depression: 82%). Conclusions: Novel computational tools can be useful in clinical practice and provide comprehensive information supporting clinicians in decisionmaking processes. ASS analyzed in a univariate way was moderately adequate, with poor accuracy compared with its implementation in an SVM classifier. SVM using whole brain segmentation yielded the highest diagnostic accuracies. Furthermore, SVM performed as well as published accuracies of pathophysiological markers of AD to distinguish this etiology from other dementias and depression. Implementation of whole brain SVM classification in clinical routine could represent a valuable diagnostic tool.